Skip to main content
SpringerLink
Log in

Monoklonale Antikörper

Monoclonal antibodies

  • Leitthema
  • Published:
Der Onkologe Aims and scope

Zusammenfassung

Heutzutage sind monoklonale Antikörper in allen Bereichen der Wissenschaft und Medizin präsent und gelten als viel versprechendste Ergänzung zu herkömmlichen therapeutischen und diagnostischen Methoden. Der Erfolg einer Immuntherapie hängt allerdings ganz entscheidend von der Effektivität und Immunogenität der Reagenzien und der Spezifität der Zielstrukturen ab. Da ein immunkompetenter Organismus Antikörper gegen Fremdproteine entwickelt, war ein Hauptziel die Entwicklung von Strategien zur Chimärisierung bzw. Humanisierung muriner Antikörper. Es gibt zurzeit 3 experimentelle Ansätze, humane monoklonale Antikörper herzustellen: über Phagenbanken (phage display), durch Immunisierung von transgenen Mäusen (HumAb-mouse) und durch die klassische Methode der somatischen Hybridisierung von B-Zellen aus Patienten (Triomatechnik).

Abstract

Nowadays, monoclonal antibodies are present in all fields of science and medicine and are regarded as a promising addition to conventional therapeutic and diagnostic methods. The success of immunotherapy, however, is crucially dependent on the effectiveness and immunogenicity of the reagents and the specificity of the targeted structures. Since an immunoincompetent organism develops antibodies against foreign proteins, a major goal was to design strategies for chimerization or humanization of murine antibodies. There are currently three experimental approaches for producing human monoclonal antibodies: by phage display, immunization of transgenic mice (HuMAb-Mouse), and classic procedures for somatic hybridization of B cells from patients (trioma technique).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3
Abb. 4
Abb. 5

Literatur

  1. Ehrlich P (1900a) The general significance of the side-chain theory, and its importance in biology and therapy. Special Pathology and Therapy 8:163–185

    Google Scholar 

  2. Ehrlich P (1900b) On immunity with special reference to cell life. Proc R Soc Lond (Biol) 66:424–428

    Google Scholar 

  3. Kohler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495–497

    CAS  PubMed  Google Scholar 

  4. Galfre G, Howe SC, Milstein C, Butcher GW, Howard JC (1977) Antibodies to major histocompatibility antigens produced by hybrid cell lines. Nature 266:550–552

    PubMed  Google Scholar 

  5. Galfre G, Milstein C (1981) Preparation of monoclonal antibodies: strategies and procedures. Methods Enzymol 73:3–46

    Google Scholar 

  6. Dickman S (1998) Antibodies stage a comeback in cancer treatment. Science 280:1196–1197

    Google Scholar 

  7. Houghton AN, Scheinberg DA (2000) Monoclonal antibody therapies-a ‚constant‘ threat to cancer. Nat Med 6:373–374

    Google Scholar 

  8. Glennie MJ, Johnson PW (2000) Clinical trials of antibody therapy. Immunol Today 21:403–410

    Google Scholar 

  9. Borchmann P, Riethmuller G, Engert A (2001) Monoclonal antibodies: development and clinical prospects. Internist 42:803–804, 807–814

    Google Scholar 

  10. von Mehren M, Weiner LM (1996) Monoclonal antibody-based therapy. Curr Opin Oncol 8:493–498

    PubMed  Google Scholar 

  11. LoBuglio AF, Wheeler RH, Trang J, Haynes A, Rogers K, Harvey EB, Sun L, Ghrayeb J, Khazaeli MB (1989) Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. Proc Natl Acad Sci U S A 86:4220–4224

    Google Scholar 

  12. Boel E, Verlaan S, Poppelier MJ, Westerdaal NA, Van Strijp JA, Logtenberg T (2000) Functional human monoclonal antibodies of all isotypes constructed from phage display library-derived single-chain Fv antibody fragments. J Immunol Methods 239:153–166

    Google Scholar 

  13. Green LL (1999) Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies. J Immunol Methods 231:11–23

    Google Scholar 

  14. Vollmers HP, O’Connor R, Müller J, Kirchner T, Müller-Hermelink HK (1989) SC-1, a functional human monoclonal antibody against autologous stomach carcinoma cells. Cancer Res 49:2471–2476

    Google Scholar 

  15. Faller G, Vollmers HP, Weiglein I, Marx A, Zink C, Pfaff M, Müller-Hermelink HK (1990) HAB-1, a new heteromyeloma for continuous production of human monoclonal antibodies. Br J Cancer 62:595–598

    Google Scholar 

  16. Clynes RA, Towers TL, Presta LG, Ravetch JV (2000) Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 6:443–446

    Article  CAS  PubMed  Google Scholar 

  17. Cragg MS, French RR, Glennie MJ (1999) Signaling antibodies in cancer therapy. Curr Opin Immunol 11:541–547

    Google Scholar 

  18. Hensel F, Hermann R, Schubert C, Abé N, Schmidt K, Franke A, Shevchenko A, Mann M, Müller-Hermelink HK, Vollmers HP (1999a) Characterisation of glycosylphosphatidyl-inositol-linked molecule CD55/Decay-accelerating factor as the receptor for antibody SC-1-induced apoptosis. Cancer Res 59:5299–5306

    Google Scholar 

  19. Groner B, Hartmann C, Wels W (2004) Therapeutic antibodies. Curr Mol Med 4:539–547

    Google Scholar 

  20. Chen YT, Boyer AD, Viars CS, Tsang S, Old LJ, Arden KC (1997a) Genomic cloning and localization of CTAG, a gene encoding an autoimmunogenic cancer-testis antigen NY-ESO-1, to human chromosome Xq28. Cytogenet Cell Genet 79:237–240

    Google Scholar 

  21. Chen YT, Scanlan MJ, Sahin U, Tureci O, Gure AO, Tsang S, Williamson B, Stockert E, Pfreundschuh M, Old LJ (1997b) A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA 94:1914–1918

    Google Scholar 

  22. Hensel F, Knörr C, Hermann R, Krenn V, Müller-Hermelink HK, Vollmers HP (1999b) Mitogenic autoantibodies in Helicobacter pylori-associated stomach cancerogenesis. Int J Cancer 81:229–235

    Google Scholar 

  23. Brändlein S, Lorenz J, Ruoff N, Hensel F, Beyer I, Müller J, Neukam K, Illert B, Eck M, Müller-Hermelink HK Vollmers HP (2002) Human monoclonal IgM antibodies with apoptotic activity isolated from cancer patients. Hum Antibodies 11:107–119

    Google Scholar 

  24. Brändlein S, Pohle T, Ruoff N, Wozniak E, Müller-Hermelink HK, Vollmers HP (2003) Natural IgM Antibodies and Immunosurveillance Mechanisms against Epithelial Cancer Cells in Humans. Cancer Res 63:7995–8005

    Google Scholar 

  25. Vollmers HP, Hensel F, Hermann R, Dämmrich J, Wozniak E, Gessner P, Herrmann B, Zimmermann U, Müller-Hermelink HK (1998a) Tumor-specific apoptosis by the human monoclonal antibody SC-1: A new therapeutical approach for stomach cancer. Oncol Rep 5:35–40

    Google Scholar 

  26. Vollmers HP, Zimmermann U, Krenn V, Timmermann W, Illert B, Hensel F, Hermann R, Thiede A, Wilhelm M, Rückle-Lanz H, Reindl L, Müller-Hermelink HK (1998b) Adjuvant therapy for gastric adenocarcinoma with the apoptosis-inducing human monoclonal antibody SC-1: first clinical and histopathological results. Oncol Rep 5:549–552

    Google Scholar 

  27. Brändlein S, Beyer I, Eck M, Bernhardt W, Hensel F, Müller-Hermelink HK, Vollmers HP (2003) CFR-1, a new marker for precancerous epithelial lesions defined by the human monoclonal antibody PAM-1. Cancer Res 63:2052–2061

    Google Scholar 

  28. Brändlein S, Pohle T, Vollmers C, Wozniak E, Ruoff N, Müller-Hermelink HK, Vollmers HP (2004) CFR-1 receptor as target for tumor-specific apoptosis induced by the natural human monoclonal antibody PAM-1. Oncol Rep 11:777–784

    Google Scholar 

  29. Hensel F, Hermann R, Brändlein S, Krenn V, Schmausser B, Geis S, Müller-Hermelink HK, Vollmers HP (2001b) Regulation of the New Coexpressed CD55 (Decay-Accelerating Factor) Receptor on Stomach Carcinoma Cells Involved in Antibody SC-1-Induced Apoptosis. Lab Invest 81:1553–1563

    Google Scholar 

  30. Pohle T, Brändlein S, Ruoff N, Müller-Hermelink HK, Vollmers HP (2004) Lipoptosis: tumor-specific cell death by antibody-induced intracellular lipid accumulation. Cancer Res 64:3900–3906

    Google Scholar 

  31. Brändlein S, Vollmers HP (2004) Natural IgM antibodies, the ignored weapons in tumour immunity. Histol Histopathol 19:897–905

    Google Scholar 

  32. Hensel F, Brändlein S, Eck M, Schmidt K, Krenn V, Kloetzer A, Bachi A, Mann M, Müller-Hermelink HK, Vollmers HP (2001a) A novel proliferation-associated variant of CFR-1 defined by a human monoclonal antibody. Lab Invest 81:1097–1108

    Google Scholar 

  33. Niehans GA, Cherwitz DL, Staley NA, Knapp DJ, Dalmasso AP (1996) Human carcinomas variably express the complement inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay-accelerating factor), and CD59 (protectin). Am J Pathol 149:129–142

    CAS  PubMed  Google Scholar 

  34. Vollmers HP, Eck M, Brändlein S, Müller-Hermelink HK, Hensel F, Urlinger S, Vinson R, Coquoz D (2004) SC-1, a human antibody for treatment of gastric carcinomas (GCs) – Results of a multi-ethnic expression sudy of the SC-1 antigen. American Society of Clinical Oncology. Ann Proc 40th ASCO Meeting: 329

    Google Scholar 

  35. Vollmers HP, Dämmrich J, Ribbert H, Wozniak E, Müller-Hermelink HK (1995) Apoptosis of stomach carcinoma cells induced by a human monoclonal antibody. Cancer 76:550–558

    Google Scholar 

  36. Vollmers HP, Dämmrich J, Ribbert H, Grassel S, Debus S, Heesemannn J, Müller-Hermelink HK (1994) Human monoclonal antibodies from stomach carcinoma patients react with Helicobacter pylori and stimulate stomach cancer cells in vitro. Cancer 74:1525–1532

    Google Scholar 

Download references

Interessenkonflikt:

Der korrespondierende Autor versichert, dass keine Verbindungen mit einer Firma, deren Produkt in dem Artikel genannt ist, oder einer Firma, die ein Konkurrenzprodukt vertreibt, bestehen.

Author information

Authors and Affiliations

  1. Pathologisches Institut, Universität Würzburg

    H. P. Vollmers & S. Brändlein

  2. Pathologisches Institut, Universität Würzburg, Josef-Schneider-Straße 2, 97080 , Würzburg

    H. P. Vollmers

Authors
  1. H. P. Vollmers
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Brändlein
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H. P. Vollmers.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vollmers, H.P., Brändlein, S. Monoklonale Antikörper. Onkologe 11, 494–501 (2005). https://doi.org/10.1007/s00761-005-0864-y

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00761-005-0864-y

Schlüsselwörter

Keywords

Search

Navigation